All News

Pharmacists and clinicians share strategies to streamline training, collaboration, and patient care with BTCEs.

A community-based initiative is proving that the path to heart health for Black men may not start in a physician’s office, but in the barber’s chair.

Disease burden, monitoring strategy, and timing of therapy drive CRS risk and management.

Historically, dulaglutide was a preferred choice because it was proven to reduce major adverse cardiovascular events in the REWIND trial.

Ivermectin, fenbendazole, and mebendazole have gained traction as alternative cancer therapies despite a lack of clinical evidence.

The RECOVER-AUTONOMIC trial underscores the necessity of better clinical end points to assess interventions in the long COVID population.

Experts discuss immunotherapy overlap, nutrition challenges, and clinical judgment with GLP-1 RA use.

CHAMPION-AF may potentially lead to a shared decision-making process between a lifetime of medication and a one-time catheter-based procedure.

Formal preceptor leadership pathways can reduce RPD burden and improve resident support across programs.

Survivor and pharmacist Kelly Gable, PharmD, BCPP, FAAPP, explains the overlooked challenges shaping patients’ day-to-day lives.

In a session at the American Pharmacists Association Annual Meeting, Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, provided practical insights for pharmacists to optimize the care of patients with cardio-kidney-metabolic conditions.

Experts detail the workflows and decisions behind launching complex bispecific therapies.

Multicenter data suggests dexamethasone may safely replace tocilizumab for low-grade CRS.

The FDA removed the age requirement from the neffy 1-mg label, allowing use based solely on weight and expanding access to younger pediatric patients at risk for anaphylaxis.

Pharmacists at the 2026 HOPA Annual Meeting discuss medical misinformation and how to combat it.

Oncology pharmacists explore how GLP-1 agents intersect with cancer treatments, overlapping toxicities, and shared decision-making.

CDC flags a late respiratory syncytial virus (RSV) rise, while the NFID urges spring vigilance, vaccines, and monoclonals to protect infants and older adults from this virus.

Joseph Saseen, PharmD, explains the 2026 dyslipidemia guidelines' push for universal lipoprotein A screening, clarifies when apolipoprotein B testing adds value, and outlines how new FDA-approved therapies fit into the updated lipid-lowering treatment algorithm.

Experts discuss real-world BTCE challenges, toxicity monitoring, and evolving pharmacy practice.

The safety and effectiveness of marne-cel were established in an open-label, single-arm, multicenter phase 1/2 clinical trial.

Volunteer service strengthens pharmacists’ empathy, confidence, and communication, boosting patient trust, teamwork, and community connection.

Practical insights for navigating rare, high-stakes toxicities.

Expert insights on toxicity management, resistance mechanisms, and frontline integration of Bruton tyrosine kinase inhibitors in MCL.

Insulin icodec-abae injection becomes the first and only once-weekly basal insulin option, offering personalized care for adults with type 2 diabetes (T2D).

New data, emerging targets, and evolving ADC use are reshaping second-line decisions.

Experts discuss the 340B Pricing Program, sharing updates, ongoing challenges, and solutions for pharmacists.

ABBV-744 BD2-selective BET inhibitor shows early spleen and symptom gains with manageable cytopenias in a phase 1b trial.